Acurx Pharmaceuticals, Inc. (ACXP) Stock Price & Analysis
Acurx Pharmaceuticals, Inc. (ACXP) fell 2.07% to USD 1.42 as of July 25, 2026 at 06:45 UTC, according to Nexqual real-time market data.
ACXP last closed at USD 1.45; the session ranged USD 1.38–1.47 on volume of 73,633 shares. Market capitalization is $6.10M, with a 52-week range of USD 1.33–9.2 (NCM). Source: Nexqual, July 25, 2026 at 06:45 UTC.
Key Statistics (as of July 25, 2026 at 06:45 UTC)
| Price | USD 1.42 |
|---|---|
| Change | ▼ 2.07% (down) |
| Previous Close | USD 1.45 |
| Open | USD 1.45 |
| Day Range | USD 1.38 – 1.47 |
| 52-Week Range | USD 1.33 – 9.2 |
| Volume | 73,633 shares |
| Market Cap | $6.10M |
| Exchange | NCM |
Technical Analysis (ACXP)
Nexqual's technical model rates ACXP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.23 (neutral) |
| vs SMA50 | Below (USD 1.66) |
| MACD | -0.05 (negative) |
Analyst Ratings (ACXP)
Wall Street analysts rate ACXP "None" based on 3 analysts, with a mean price target of USD 17 (range USD 10–31), per Nexqual as of July 25, 2026 at 06:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 17 |
| High Target | USD 31 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (ACXP)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.62 vs est -0.64 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -1 ▲ beat |
| 2025-09-30 | USD -1.23 vs est -1.49 ▲ beat |
| 2025-06-30 | USD -1.89 vs est -2.1 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:45 UTC.
Financials & Fundamentals (ACXP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -160.83% |
| Current Ratio | 3.78 |
| Total Cash | $9.25M |
| Total Debt | $0 |
| Free Cash Flow | $-3.42M |
Source: Nexqual, July 25, 2026 at 06:45 UTC.
Financial Health Score (ACXP)
Nexqual rates Acurx Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -161%, ROA -66.5% |
Ownership (ACXP)
| Insider Ownership | +2.99% |
|---|---|
| Institutional Ownership | +6.17% |
| Shares Outstanding | 4.30M |
| Float | 4.17M |
| Short % of Float | +2.46% |
Source: Nexqual, July 25, 2026 at 06:45 UTC.
Leadership (ACXP)
Acurx Pharmaceuticals, Inc. is led by David P. Luci CPA, Esq. (age 58), Co-Founder, President, CEO, Corporate Secretary & Director, per Nexqual as of July 25, 2026 at 06:45 UTC.
| Co-Founder, President, CEO, Corporate Secretary & Director | David P. Luci CPA, Esq. (age 58) |
|---|---|
| Co-Founder & Executive Chairman | Robert J. DeLuccia (age 79) |
| Co-Founder & CFO | Robert G. Shawah (age 58) |
| Medical Director | Michael H. Silverman B.Sc., F.A.C.P., FACR (age 77) |
Major Backers & Investors (ACXP)
Notable institutional backers of Acurx Pharmaceuticals, Inc. include Jane Street Group, LLC, Cambridge Investment Research Advisors Inc., Fidelity, according to Nexqual as of July 25, 2026 at 06:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 1.27% |
| Cambridge Investment Research Advisors Inc. | 0.47% |
| Fidelity | 0.47% |
| Prospect Financial Services LLC | 0.32% |
| UBS Group AG | 0.15% |
| Morgan Stanley | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.82% |
| Geode Capital | 0.58% |
Source: Nexqual, July 25, 2026 at 06:45 UTC.
From Acurx Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
- The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
- It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.13 | ▼ 3.62% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| ABVC | ABVC Biopharma, Inc. | USD 1.15 | ▼ 2.54% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:45 UTC. This page is informational and not investment advice.